Background
Breast cancer (BC) is the most common malignancy in women, and globally accounts for approximately 685,000 deaths annually. The majority of BC (70%) is estrogen receptor alpha positive (ER
+) upon diagnosis. The current standard of care includes the use of endocrine therapies such as tamoxifen the oldest and most prescribed selective estrogen receptor modulator, anti-estrogens, selective estrogen receptor degraders, and aromatase inhibitors which are widely used for the treatment of ER
+ BC. However, over time approximately 30–40% of patients develop resistance to these treatment options, and this represents a major clinical problem [
1‐
3]. Several lines of evidence suggest that multiple pathways including oncogenic growth factor signaling [
4,
5], epigenetic changes [
6], activation of the PI3K/Akt/mTOR pathway [
7], and alterations of levels of ER coregulators [
8] contribute to endocrine therapy resistance. However, the molecular mechanisms that contribute resistance to endocrine therapy are not completely understood.
SETDB1 (SET domain bifurcated 1), is a methyltransferase involved in di and tri-methylation of H3K9 and is implicated in repression of transcription [
9]. Deregulation of SETDB1 expression occurs in many cancers [
10]. In fact, SETDB1 is amplified in triple negative breast cancers (TNBC) [
11] and is shown to regulate TNBC metastasis by enhancing stem-cell-like properties and modulating the epithelial-mesenchymal transition (EMT) program [
12]. Recent studies also suggest that SETDB1 is localized both in the nucleus and cytoplasm. Further, SETDB1 mediated Akt K64 methylation promotes Akt hyperactivation resulting in cancer progression [
13]. However, the molecular mechanisms by which SETDB1 contributes to ER
+ BC progression to endocrine therapy resistance is poorly understood.
Proline-, glutamic acid-, and leucine-rich protein 1 (PELP1) is a scaffolding protein that functions as a coregulator of several nuclear receptors including ER [
14]. PELP1 oncogenic signaling is implicated in BC progression [
15,
16] and transgenic mice with PELP1 overexpression in the mammary glands develop mammary gland carcinoma [
17]. PELP1 is a known prognostic indicator of poorer BC survival [
18], and its dysregulation has been shown to contribute to BC therapy resistance [
19,
20]. Furthermore, patients whose breast tumors exhibit high levels of cytoplasmic PELP1 respond poorly to tamoxifen [
21]. However, the mechanisms by which PELP1 contributes to endocrine therapy resistance remains elusive.
In this study, we found that PELP1 functions as an important regulator of SETDB1. RNA-seq studies revealed that SETDB1 participates in the regulation of a subset of ER target genes that contribute to tamoxifen therapy resistance. Mechanistic studies showed that PELP1 interacts with SETDB1 and plays a critical role in the activation of Akt by facilitating Akt methylation. Further, SETDB1 overexpression promoted tamoxifen therapy resistance and PELP1 is necessary for SETDB1 mediated Akt signaling leading to therapy resistance in ER+ BC cells. Our studies have identified a novel mechanism by which the PELP1/SETDB1 axis contributes to tamoxifen therapy resistance via activation of Akt. These findings are functionally significant as increased expression of both PELP1 and SETDB1 occur in ER+ BC. Therefore, the PELP1-SETDB1 axis could serve as a potential therapeutic target for treating endocrine therapy resistance.
Methods
Cell cultures and reagents
MCF7, ZR75, and HEK293T cell lines were purchased from the American-Type Culture Collection (ATCC) and maintained in ATCC recommended medium. All model cells utilized were free of mycoplasma contamination and STR DNA profiling of the cells was used to confirm identity. MCF7-TamR cells were cultured in medium supplemented with 1 µmol/L of tamoxifen (H7904, Sigma, St. Louis, MO). MCF7-FR cells were cultured in medium supplemented with 1 µmol/L of fulvestrant (MedChem Express, Monmouth Junction, NJ) for 6 months to develop resistance. The SETDB1 antibody (11231-1-AP) was obtained from Proteintech (Rosemont, IL). The PELP1 antibody (A300-180A) was purchased from Bethyl Laboratories (Montgomery, TX). The ERα (04-820) and β-Actin antibodies (A-2066) were purchased from Millipore Sigma (Burlington, MA). The phospho-ER (Ser167) antibody (PA5-37570) was purchased from Invitrogen (Waltham, MA). The mCherry antibody (632543) was obtained from Takara Bio (San Jose, CA). The GFP antibody (632460) was obtained from Clontech. Antibodies for GST (2624), p-Akt (4060), Akt (9272), tri-methyl lysine motif (K-me3,14680) and GAPDH (8884) were purchased from Cell Signaling Technology (Beverly, MA). For IHC analysis, Ki67 antibody (ab16667) was purchased from Abcam (Cambridge, MA) and p-Akt (05-1003) antibody was purchased from Millipore Sigma.
Generation of model cell lines
MCF7 and ZR75 cells stably expressing SETDB1-shRNA were generated using lentivirus expressing SETDB1 shRNA (TRCN0000276169, TRCN0000276105, Sigma). MCF7 and ZR75 cells stably expressing PELP1-shRNA were created using validated human specific lentiviral PELP1-shRNA particles (TRCN0000159883, Sigma). MCF7 cells expressing T7-cyto-PELP1 were earlier described [
22]. MCF7 and ZR75 cells stably expressing SETDB1 were generated using pLV-Bsd-EF1A-SETDB1 vector. HEK293T cells expressing GFP-SETDB1 were generated using pLV-Bsd-EF1A-EGFP-SETDB1 vector. MCF7, ZR75 and HEK293T cells expressing mCherry-cyto-PELP1 were generated using pLV-Hygro-EF1A-Cherry-PELP1-Cyto-NLSmt (KKK to EEE) vector. HEK293T cells stably expressing GST-Akt were created using the lentiviral vector pLV-Hygro-EF1A-GST-AKT. Lentiviral particles expressing non-targeted shRNA (SHC016-1EA, Sigma), GST-vector (pLV-Puro-EF1A-GST vector), mCherry-vector (pLV-mCherry-Puro-EF1A vector) were used to generate control cells. All the vectors are custom made by Vector Builder (
https://en.vectorbuilder.com). Stable clones were generated using puromycin (1 μg/mL) or hygromycin (100 μg/mL) selection and pooled clones were used for all studies.
Reporter gene assays
HEK293T cells stably expressing ERE firefly luciferase reporter and ERα were transfected with SETDB1 expressing vector or control vector using Turbofect transfection reagent (Thermo Fisher Scientific, Waltham, MA). MCF7 cells stably expressing SETDB1-shRNA or non-targeted shRNA were transduced with ERE luciferase reporter. The Renilla reporter plasmid was co-transfected and used for data normalization. After 48 h, cells were treated with E2 (10–8 M) for 24 h and luciferase activity was measured using the Dual luciferase assay system (Promega, Madison, WI) using a luminometer.
Yeast-two hybrid, immunoprecipitation and Western blot assays
Mapping of the PELP1-SETDB1 interaction region using yeast-two hybrid assay was done as described [
23]. Yeast cells were co-transfected with a gal4 activation domain (GAD) fusion GAD-SETDB1, along with gal4 binding domain (GBD) vector or GBD fusions of various domains of PELP1. Growth was recorded after 72 h on selection plates lacking leucine and tryptophan (− LT) or adenine, histidine, leucine, and tryptophan (− AHLT). BC cells were stimulated either with E2 or 10% fetal bovine serum (FBS). For E2 stimulation, MCF7 and ZR75 cells were cultured in Dextran Coated Charcoal stripped serum (DCC) supplemented medium for 48 h and then stimulated with E2 (10
–8 M). To simulate the growth factor driven signaling, MCF7 and ZR75 model cells were serum-starved for 24 h and stimulated with medium containing 10% serum. Cell lysates were prepared by RIPA buffer (Thermo Fisher Scientific) containing protease and phosphatase inhibitors and Western blot analysis was performed. For co-immunoprecipitation analysis, the lysates were incubated with indicated antibody or IgG control overnight at 4 °C, and then incubated with Protein A/G beads (Thermo Fisher Scientific) for 2 h, overnight incubation with GST beads (17-0756-01, GE Healthcare, Chicago, IL) or T7 Tag Antibody Agarose (69026, Novagen) or GFP-TRAP and RFP-TRAP Agarose (ChromoTek) at 4 °C. Interactions were analyzed by Western blotting using indicated antibodies. For GST pull-down assays, GST-tagged Akt1 protein was purified from HEK293T cells.
In vitro methylation assay
Purification of PELP1 protein was done using baculovirus system as earlier described [
24]. GST-tagged Akt1 protein was purified from HEK293T cells using GST-pull down assay. Recombinant SETDB1 protein was purchased from Active Motif (cat#31452, Carlsbad CA) and manufacturer’s protocol was followed for the methylation assay. Briefly, SETDB1, Akt and PELP1 proteins were incubated in 50 mM Tris–HCl (pH 8.6), 0.02% Triton X-100, 2 mM MgCl
2, 1 mM TCEP, 50 µM S-adenosyl-methionine (SAM) buffer for 4 h at 37 °C. The reaction was stopped by the addition of Laemmli reducing sample buffer and run on 8% electrophoresis gel.
Cell viability, clonogenic assays and three-dimensional cell culture
Cell viability was determined using MTT assay as described [
25]. For the clonogenic assays, model cells (500 cells/well) were seeded in 6 well plates and survival was analyzed after 14 days. To test the drug effect on colony formation, the model cells were treated with E2 (10
–8 M) in the presence or absence of tamoxifen or Mithramycin A (Millpore Sigma) for 5 days and allowed to grow for another 7 days. The cells were fixed in ice-cold methanol and stained with 0.5% crystal violet solution. For 3D cell culture, model cells suspended in matrigel (6 × 10
3/40 μL) were plated onto a culture plate, incubated at 37 °C for 10 min to solidify and subsequently cultured for 10 days in DMEM/F12 growth medium. The relative size of the colonies was analyzed by ImageJ software.
Total RNA from MCF7 cells stably expressing control non-targeted shRNA or SETDB1 shRNA was isolated using RNeasy mini kit (Qiagen). The RNA-Seq library was prepared using Illumina TruSeq stranded mRNA Sample preparation kit (Illumina) and sequencing was performed at Greehey Children’s Cancer Research Institute Genome Sequencing Facility (UT Health, SA) using 50 bp single read sequencing module with Illumina HiSeq 3000 sequencing platform. Sequence reads were mapped to UCSC hg19 genome using TopHat2 aligner and quantified to NCBI RefSeq genes using HTSeq [
26]. Differential expression analysis was conducted using DEseq2 [
27] and significant genes with fold change > 2 and adjusted
p value < 0.05 were used for interpreting functional enrichment pathways. Gene set enrichment analysis (GSEA) (
http://www.broadinstitute.org/gsea/index.jsp) [
28] was used to perform gene set enrichment analysis. The Pheatmap package (1.0.12) was used to create heatmaps of differential genes. PELP1 RNA-seq analysis results used in this study was previously published [
29]. RNA-seq data has been deposited in the GEO database under GEO accession number GSE187398. Biological network integration for prediction of gene interaction was done by GeneMANIA prediction server [
30]. Biomolecular interaction networks were visualized using Cytoscape (V.3.8.2) [
31]. Tumor subgroup SETDB1 gene expression analyses was done using UALCAN [
32]. Comparison of SETDB1 gene expression in normal and breast tumor tissues was done by TNMplot [
33]. Gene-expression correlation analyses of TCGA breast cancer dataset was done using bc-GenExMiner 3.0[
34]. For Real-time quantitative PCR (RT-qPCR) analyses total RNA was isolated using Trizol Reagent (Invitrogen). Reverse transcription was performed using SuperScript III First Strand kit (Invitrogen). RT-qPCR was done using SYBR Green (Thermo Fisher Scientific) with the primers included in the Additional file
1.
In vivo xenograft studies
All animal studies were conducted after obtaining UT Health San Antonio IACUC approval, and in accordance with IACUC guidelines. SCID mice (
n = 5, per group) were implanted with E2 pellet (cat# SE-121, Innovative Research of America, Sarasota, FL) as described previously [
35]. Model cells MCF7-Control, MCF7-SETDB1, MCF7-PELP1-KD, MCF7-PELP1-KD + SETDB1 (2 × 10
6 cells) were mixed with equal volume of matrigel and injected orthotopically into the mammary fat pads of 8-week-old SCID mice. Tumor growth was measured using calipers at weekly intervals, and tumor volume was calculated using a modified ellipsoidal formula: tumor volume = 1/2(L × W
2), where W is the transverse diameter and L represents longitudinal diameter. At the end of the experiment, mice were euthanized, and tumors were processed for histological studies.
Immunohistochemistry (IHC) analyses
Immunohistochemical analysis was conducted using an established protocol [
25]. Briefly, sections were blocked with normal horse serum (Vector Labs, Burlingame, CA) followed by overnight incubation with primary antibody [Ki-67 (1:100); p-Akt(S473) (1:100)] and subsequent secondary antibody incubation for 30 min at room temperature. Percentage of Ki-67 positive cells and the staining intensity of p-Akt (S473) was calculated in five randomly selected microscopic fields. Quantification of D-HSCORE value was done by ImageJ software as described previously [
36].
Statistical analysis
The student’s t-test and one-way ANOVA were used to analyze the statistical differences with GraphPad Prism 7 software (GraphPad Prism Software, San Diego, CA). All the data represented in bar graphs are shown as mean ± SEM. A value of p < 0.05 was considered as statistically significant.
Discussion
SETDB1 plays an oncogenic role in the progression of many cancers including breast cancer [
10]. However, the mechanisms by which SETDB1 promotes endocrine therapy resistance in ER
+ BC remain elusive. In this study, using ER + BC models we provided evidence that SETDB1 does play an important role in the regulation of subsets of ER and Akt target genes. Our studies discovered that PELP1 is a novel interacting protein of SETDB1 and demonstrated PELP1 is needed for SETDB1 mediated oncogenic functions and endocrine therapy resistance. Further, our studies showed that PELP1 plays an essential role in the activation of oncogenic Akt signaling by enhancing SETDB1 mediated methylation of Akt. Finally, we demonstrated that PELP1 plays a critical role in SETDB1 mediated tumor progression in vivo. Collectively, these findings implicate the important role of the PELP1/SETDB1 axis in ER
+ BC progression and development of endocrine therapy resistance.
SETDB1 is a known oncogene, and its high expression correlate with worse overall survival, and shorter relapse-free survival [
42]. SETDB1 enhances c-MYC and cyclin D1 expression, and thus provides a growth advantage to breast cancer cells [
43]. In addition, SETDB1 is also known to regulate metastases in TNBC cells [
44] and EMT by regulating expression of the transcription factor Snail [
45]. Our results using RNA-Seq showed that SETDB1-regulated genes are positively correlated with ER signaling, tamoxifen resistance and PI3K-Akt signaling. Our studies identified PELP1 as a novel interactor of SETDB1 using yeast based two hybrid screen and PELP1 enhances SETDB1 mediated Akt methylation. Further, SETDB1 and PELP1-regulated genes in ER
+ BC are positively correlated with ESR1 targets via Akt1 signature. RNA-Seq data suggested SETDB1 regulate a number of pathways in BC cells and some of these pathways are common to PELP1 regulated pathways, while others are PELP1 independent. Our previous studies showed that cytoplasmic PELP1 signaling contributes to endocrine resistance; however the mechanism is not clear. In the present study, our results suggest that PELP1/SETDB1 complex mediated extranuclear functions and endocrine resistance occur via AKT1 and PELP1 knockdown compromises these functions. However, in this study, we did not examine the other SETDB1 mediated functions including epigenetic changes, p53 signaling, cell cycle, EMT, and metastases. Future studies are needed to determine whether PELP1plays a role in other SETDB1 mediated functions.
SETDB1 is a methyltransferase involved in di and tri-methylation of histone H3 at K9 [
9] Recent studies identified that SETDB1 also methylates non-histone substrates. In fact, SETDB1 interacts with Akt [
46], methylates Akt at K64 or K140 to elicit Akt ubiquitination, cell membrane recruitment, phosphorylation and subsequent activation upon stimulation by growth factors [
13,
40]. Our results also suggest that PELP1 plays an essential role in the activation of Akt by SETDB1. Using in vitro and in vivo methylation assays, we provided evidence that PELP1 enhances the methylation of Akt by SETDB1. Furthermore, knockdown of PELP1 substantially reduced SETDB1 mediated Akt methylation, Akt phosphorylation and ER phosphorylation. A limitation of mechanistic studies and biological assays conducted in our study is that it only focused on SETDB1-mediated extra nuclear functions via Akt1 that contribute to endocrine resistance and cell survival. Since both PELP1 and SETDB1 are also present in the nucleus, they may have additional functions in the nuclear compartment. Future studies are needed to examine the significance of PELP1 on SETDB1 mediated nuclear functions.
PELP1 oncogenic signaling is implicated in the progression of several cancers including breast r [
47]. It is well documented that PELP1 expression is an independent prognostic predictor of shorter breast cancer–specific survival and disease-free interval [
18], and PELP1 dysregulation contributes to BC therapy resistance [
19,
20]. Hormonal therapies using tamoxifen and fulvestrant induce a pro-invasive and pro-migratory phenotype in ER
+ BC and exhibit a high basal expression of PELP1 [
48]. The PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases has been shown to drive therapy resistant ER + BC [
49] and cytoplasmic PELP1/SRC-3 signaling complexes increase BC stem cells [
50]. ER + BC tumors with high levels of cytoplasmic PELP1 exhibit poor response to tamoxifen treatment [
21]. Our data suggests that SETDB1-PELP1 interactions play a key role in endocrine resistance and that the PELP1 localization to the cytoplasm, commonly seen in breast tumors, may play a role in enhancing SETDB1 oncogenic signaling. Further, our results suggest that PELP1 plays an essential role in SETDB1 mediated endocrine therapy resistance as PELP1 knockdown reduced SETDB1 mediated therapy resistance to endocrine therapies.
Our analyses of TCGA datasets revealed that both SETDB1 and PELP1 are commonly overexpressed in BC. We found that endocrine therapy resistant models express higher levels of SETDB1 and the down regulation of SETDB1 expression sensitizes them to endocrine therapy. Our results also suggested that PELP1 plays an essential role in SETDB1 mediated BC progression to endocrine therapy resistance. Further, our results support that SETDB1 is a novel PELP1 binding protein. Accordingly, SETDB1 expression is positively correlated with PELP1 expression in ER+ BC patients. Since, dysregulated Akt signaling has been linked to ER + BC progression and endocrine therapy resistance, we predict that the commonly deregulated SETDB1-PELP1 axis may contribute to hyperactive Akt signaling leading to BC progression and endocrine therapy resistance. As of now, no specific inhibitors of SETDB1 are currently available. Previous studies have demonstrated that Mithramycin A reduce the expression of SETDB1 by targeting the SP1 transcription factor which regulate expression of SETDB1 [
51,
39]. Our results using SETDB1 KD or reduction of SETDB1 levels via Mithramycin A treatment provided evidence for the utility of targeting SETDB1 in sensitizing endocrine therapy resistant ER
+ BC cells. However, development of a specific inhibitor of SETDB1 is needed for future translation of these findings.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.